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Introduction
Numerous proteins mediate the intra-and extra-cellular binding and transport of fatty acids, which both facilitates the physiological functions of fatty acids while minimizing cellular exposure to high (and potentially toxic) concentrations of these compounds. Albumin is the most abundant fatty acid binding protein, and is also the best characterized in terms of structure and function (Hamilton, 2004) . Apart from functioning as the primary plasma transporter of unesterified fatty acids, serum albumin also binds a myriad of endogenous and exogenous compounds, including drugs with acidic or electronegative features.
Like albumin, members of the intracellular fatty acid binding family of proteins (FABPs) , which are amongst the most abundantly expressed cytosolic proteins, bind saturated and unsaturated long-chain fatty acids with high affinity (Veerkamp and Maatman, 1995; Zimmermann and Veerkamp, 2002; Chumurzynska, 2006) . Within the cell, FABPs solubilize and transport fatty acids, and function more generally as lipid chaperones that coordinate the biological actions of fatty acids (Furuhashi and Hotamisligil, 2008) . To date, nine human FABPs, each with a characteristic tissue distribution, have been identified (Chumurzynska, 2006; Furuhashi and Hotamisligil, 2008) . The intestinal FABP (IFABP) is expressed along the entire length of the small intestine, although most abundantly in the medial segment, and accounts for approximately 3% of enterocyte cytoplasmic protein (Vassileva et al., 2000; Agellon et al., 2002) . Rat IFABP binds a single molecule of fatty acid in a slightly bent conformation (Sacchatteni et al., 1989; Zhang et al., 1997) . The carboxylate head group of the fatty acid is deeply buried in the ligand binding site, where it hydrogen-DMD 27656 6 bonds with arginine-106 (Hamilton, 2004) . Although it is known that rat IFABP and liver FABP (LFABP) bind a number of acidic and neutral drugs with varying affinities (Velkov et al., 2005 and Chuang et al., 2008) , the binding of drugs to human IFABP has not been characterized.
In addition to its endogenous 'binding' roles, albumin has been included as a constituent of microsomal incubations in experiments to generate kinetic parameters for drug and xenobiotic metabolism. In vitro approaches for the prediction of drug pharmacokinetic parameters in vivo (in vitro -in vivo extrapolation; IV-IVE), particularly intrinsic clearance (CL int ) and hepatic clearance (CL H ), have attracted widespread interest in recent years (Houston, 1994; Iwatsubo et al., 1997; Obach et al., 1997; Miners et al., 2006) . However, there is a bias towards under-prediction of CL int and CL H for drugs metabolized by UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP), particularly when human liver microsomes (HLM) are employed as the enzyme source (Boase and Miners, 2002; Miners et al., 2004 and 2006; Ito and Houston, 2005; Brown et al., 2007) .
Recent studies have demonstrated that this discrepancy arises to a large extent from the release of membrane long chain unsaturated fatty acids which act as potent competitive inhibitors of several UGT and CYP enzymes, resulting in over-estimation of the Michaelis constant (K m ) and hence under-prediction of microsomal CL int (Tsoutsikos et al., 2004; Rowland et al., 2007 Rowland et al., , 2008a Rowland et al., and 2008b . Addition of bovine serum albumin (BSA) or essentially fatty acid free HSA (HSA-FAF) to HLM sequesters the inhibitory long chain unsaturated fatty acids and improves prediction accuracy of the in vivo CL H values for substrates of UGT1A9, UGT2B7 and CYP2C9 This article has not been copyedited and formatted. The final version may differ from this version. (Rowland et al., 2007 (Rowland et al., , 2008a (Rowland et al., and 2008b . For example, the K m value for the glucuronidation of the UGT2B7 substrate zidovudine (AZT) by HLM was decreased by an order of magnitude in the presence of BSA, with a corresponding increase in CL int .
However, many drugs and non-drug xenobiotics that are metabolized by these enzymes bind extensively to albumin. Characterization of the kinetics of metabolite formation of such drugs by incubations of HLM supplemented with albumin presents significant difficulties given the requirement to measure the low unbound concentration of substrate in microsomal incubations. Thus, the availability of a protein which binds drugs to a lesser extent than fatty acids would be a valuable development in IV-IVE. Here, we report for the first time the binding of acidic, basic and neutral compounds (Figure 1) cDNA encoding IFABP was PCR amplified from the human IFABP cDNA. To facilitate the purification of the IFABP, six histidine residues were added to the Cterminus of wild-type IFABP cDNA using the primers:
IFABP-His 5
5'-ATTAGGATCCAAATGAGTTTCTCCGGCAAGTAC-3'
IFABP-His 3
5'-ATTATCTAGAGATCAGTGATGGTGATGGTGATGATCCTTTTTAAAGATC CTTTTGGCTTC-3'
The IFABP insert was ligated into the pCWori(+) bacterial expression plasmid. pCW-IFABP was transformed into DH5α E.coli cells and colonies were screened for the correct plasmid by restriction enzyme analysis. Plasmid DNA was purified and the nucleotide sequence was confirmed on both strands by sequencing (ABI Prism 3100).
Overnight sub-cultures (4mL) grown in Luria-Bertani broth with ampicillin (100mg/L) at 37°C were used to inoculate 400mL cultures of modified Terrific broth containing 100mg/L ampicillin. Cultures were grown at 37°C with shaking (180rpm) for 3hr, or until an optical density of approximately 0.7 at 600nm was attained, at which time the temperature was reduced to 30°C and isopropyl-b-Dthiogalactopyranoside (1mM) was added. Cultures were grown at 30°C with shaking (150rpm) for an additional 40hr. Cells were then harvested by three passages through a French press cell at a cell pressure of 8 to 11kPa. IFABP was recovered in the soluble fraction after centrifugation at 45000g for 90 min and then purified by chromatography on a pre-equilibrated Ni 2+ affinity (Ni-NTA agarose) column according to the general procedure of Johnson et al. (2005) . The concentration of purified IFABP protein was determined according to the Lowry procedure.
This article has not been copyedited and formatted. The final version may differ from this version. 1:1000 dilution). Prior to development, the membrane was washed in Tween 20. The BM chemiluminescence blotting substrate was used for immunodetection. The membrane was exposed to Kodak X-Omat films for 10sec and films were processed manually using AGFA G153 developer and G354 fixer.
AZT glucuronidation assay
Incubations, in a total volume of 0.2mL, contained phosphate buffer (0.1M, pH 7.4), MgCl 2 (4mM), HLM (0.05mg), BSA or IFABP (0 to 2.5%), and AZT (10 to 3000µM). HLM were fully activated by the addition of the pore-forming polypeptide alamethicin (50µg/mg protein) with incubation on ice for 30min (Boase and Miners, 2002) . Following a 5min pre-incubation at 37°C, reactions were initiated by the addition of 5mM UDPGA. Incubations were performed at 37°C in a shaking water bath for 60min. Reactions were terminated by the addition of 6µl of perchloric acid (70%, v/v). Samples were subsequently centrifuged at 4000g for 10min, and a 30µL aliquot of the supernatant fraction was injected directly into the HPLC column.
Zidovudine ß-D-glucuronide formation was quantified by HPLC as described by Rowland et al. (2007) .
Measurement of ANS binding and competitive displacement by ligands
This article has not been copyedited and formatted. The final version may differ from this version. The binding of ANS to IFABP and BSA was quantified by fluorescence spectroscopy using a modification of the method of Norris and Spector (2002) . Spectrofluorometer (Perkin Elmer 300) excitation and emission wavelengths were set at 370 and 475nm, respectively, with respective excitation and emission slit widths of 2.5 and 5nm. The incubation samples were titrated with eight 10μL aliquots of arachidonic acid, resulting in an ANS concentration range of 25 to 1000nM. In drug displacement studies, incubation samples containing phosphate buffer (0.1M, pH7.4), IFABP or BSA (500μg/mL) and ANS (50μM) were titrated with competitor ligand (phenytoin and torsemide; 100nM to 50μM).
Measurement of drug binding to IFABP and BSA
The binding of drugs to IFABP and BSA was measured using Microcon centrifuge filter devices (Millipore Corporation, Bedford, MA), which comprise reservoir and filtrate compartments separated by a 3kDa cellulose membrane. The cellulose membranes were conditioned with 500μL of phosphate buffer (0.1M, pH 7.4).
Incubation samples (total volume 110μL) contained the drug of interest, phosphate buffer (0.1,M pH 7.4) and protein (IFABP or BSA; 0 to 0.5%). Samples were incubated in a shaking water bath at 37°C for 120min, after which time a 100μL
This article has not been copyedited and formatted. The final version may differ from this version. It should be noted that conditioning of the membrane prior to use overcame the nonspecific binding and poor recovery reported in certain previous studies that have measured protein binding using centrifugation filter devices. Recovery, assessed by mass balance against an unfiltered sample, was ≥ 95% for all drugs. In addition, the fu values for the binding of AZT, lignocaine, phenytoin and propofol to BSA measured here (see Results) were in close agreement to those determined previously in this laboratory using equilibrium dialysis (Rowland et al., 2007 (Rowland et al., , 2008a (Rowland et al., and 2008b JO Miners and DJ Elliot, unpublished data) .
Quantification of drug binding to IFABP and BSA
Drug present in the filtrate from binding experiments was separated on a Waters
NovaPak C18 analytical column (3.9 x 150mm, 4µm, Waters, Sydney, Australia) using a mobile phase comprising 10mM triethylamine (pH adjusted to 2.5 with perchloric acid; mobile phase A) and acetonitrile (mobile phase B), at a flow rate of 1mL/min (see Supplemental Table 2 
for proportions). Column eluant was monitored
This article has not been copyedited and formatted. The final version may differ from this version. at the optimal wavelength (determined by spectroscopic analysis) for each drug (Supplemental Table 2 ). The concentration of drug in ultra-filtration samples was determined by comparison of peak areas to those of authentic standards using calibration curves that spanned the concentration ranges employed in binding studies.
Data analysis
All data points represent the mean of duplicate estimates (<10% varaiance). Kinetic unsaturated long chain fatty acids to rat IFABP (Richieri et al., 1994; Velkov et al., 2005) .
Comparative binding of drugs to IFABP and BSA
This article has not been copyedited and formatted. The final version may differ from this version. Preliminary experiments were performed to assess the binding of phenytoin (an acid),
propofol (a neutral compound) and propranolol (a base) to IFABP and, for comparison, to BSA. Binding was measured at three drug concentrations which spanned the known K m for each substrate at each of four protein concentrations, ranging from 0.05% (0.5mg/mL) to 0.5% (5mg/mL). Values of fu for phenytoin, propofol and propranolol in the presence of IFABP and BSA are shown in Table 1 . As observed previously (Rowland et al., 2008a) , phenytoin bound appreciably to BSA; torsemide to BSA were best described by a two binding mode equation (Table 3 and Figure 4 ). In contrast, data for the binding of torsemide to IFABP were best fit to the single binding mode equation (Figure 4 ). (Table 4 and Figure 5 ). K m values for AZT glucuronidation in the presence of 0.5 and 1.5%
Effect
IFABP were approximately 2 to 3-fold higher than those observed in the presence of the same concentration of BSA. However, K m values determined in the presence of 2.5% of each protein were similar (Table 4 and Figure 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. IFABP. Binding affinities and capacities measured for phenytoin and torsemide at 0.5% w/v protein were in broad agreement with these observations. Based on fu values, phenytoin binds 'moderately' to both BSA and IFABP whereas torsemide binds much more avidly to BSA ( Table 2) . Binding of torsemide to BSA occurs at two sites, with high total capacity compared to the single IFABP site (Table 3 ). In contrast, K d values and capacities for the binding of phenytoin to BSA and IFABP were of a similar order (Table 3 ). The observation of two modes for the binding of phenytoin to IFABP is consistent with the docking of ibuprofen and bezafibrate into the binding cavity of rat IFABP x-ray crystal structure which suggests that, unlike fatty acids, some acidic drugs may bind to IFABP in two orientations (Velkov et al., 2005) . It should be noted that the molecular masses of IFABP (≈15kDa) extensively to albumin at concentrations added to incubations of HLM, which is apparent from data presented in Table 2 .
The lower binding observed here with IFABP suggested that this protein may indeed represent an alternative to BSA for enhancing the prediction accuracy of IV-IVE based on human liver microsomal kinetic data. To confirm this, the kinetics of AZT glucuronidation by HLM were characterized in the absence and presence of BSA and IFABP (0.5 -2.5% w/v). Both proteins decreased the K m for zidovudine glucuronidation without affecting V max , as reported previously with BSA and HSA-FAF (Rowland et al., 2007) . However, a higher content of IFABP (2.5% vs. 1%; Table 4 and Rowland et al., 2007) 
